Clinical Trials · NCT04293393
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Spanish Breast Cancer Research Group
- Enrollment
- 200
- Start date
- Oct 2020
- Locations
- 28 sites, Spain
- Primary endpoint
- Residual Cancer Burden (RCB) 0-I Rate